argenx SE/$ARGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,599
ISIN
US04016X1019
Website
argenx SE Metrics
BasicAdvanced
$34B
35.14
$15.94
0.17
-
Price and volume
Market cap
$34B
Beta
0.17
52-week high
$658.93
52-week low
$519.70
Average daily volume
321K
Financial strength
Total debt to equity
0.71
Interest coverage (TTM)
79.79%
Profitability
EBITDA (TTM)
190.978
Gross margin (TTM)
49.59%
Net profit margin (TTM)
40.26%
Operating margin (TTM)
8.14%
Effective tax rate (TTM)
-194.04%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Valuation
Price to earnings (TTM)
35.14
Price to revenue (TTM)
12.771
Price to book
5.28
Price to tangible book (TTM)
5.46
Growth
Revenue change (TTM)
82.13%
Earnings per share change (TTM)
-382.53%
3-year revenue growth (CAGR)
90.69%
10-year revenue growth (CAGR)
81.32%
3-year earnings per share growth (CAGR)
11.40%
Bulls say / Bears say
argenx SE reported a significant increase in revenue, with a 95.7% rise to $807.37 million in Q1 2025, surpassing analyst expectations of $795.72 million. (reuters.com)
The U.S. FDA approved a pre-filled syringe version of argenx's immune disorder drug, Vyvgart, enhancing patient convenience and potentially expanding market reach. (reuters.com)
Analysts have raised price targets for argenx, with Wells Fargo increasing its target to $547, citing strong earnings and revenue growth prospects. (investing.com)
argenx's phase III ADDRESS study for efgartigimod in pemphigus failed to meet its primary endpoint, leading to a 25.1% drop in share price on December 20, 2023. (finance.yahoo.com)
Sei Investments Co. reduced its stake in argenx by 3.7% during Q4 2024, indicating potential concerns among institutional investors. (marketbeat.com)
Despite strong financial performance, argenx faces competition from established players like Regeneron, which reported robust sales for its eczema and eye disease treatments. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
argenx SE News
AllArticlesVideos
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewsWire·7 days ago
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
GlobeNewsWire·2 weeks ago
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of $34B as of June 27, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 35.14 as of June 27, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.